InsiderTrades.com logo
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.
Elizabeth E. Reed net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Elizabeth Reed Biography and Net Worth

SVP of Travere Therapeutics
Elizabeth Reed serves as senior vice president, general counsel and corporate secretary of Travere Therapeutics. She has been with the company since January 2017, and is responsible for overseeing the company’s general legal, intellectual property, government affairs and corporate compliance functions.

Previously, Ms. Reed served as general counsel of Celladon Corporation, and prior to Celladon, served as general counsel of Anadys Pharmaceuticals, Inc. until Anadys’ acquisition by Roche. Prior to joining Anadys, she was an attorney with the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California, and received her law degree from Harvard Law School and her bachelor’s in business administration from the University of California at Berkeley.

What is Elizabeth E. Reed's net worth?

The estimated net worth of Elizabeth E. Reed is at least $302,023.26 as of January 23rd, 2024. Ms. Reed owns 56,034 shares of Travere Therapeutics stock worth more than $302,023 as of April 26th. This net worth approximation does not reflect any other assets that Ms. Reed may own. Additionally, Ms. Reed receives an annual salary of $713,630.00 as SVP at Travere Therapeutics. Learn More about Elizabeth E. Reed's net worth.

How old is Elizabeth E. Reed?

Ms. Reed is currently 53 years old. There are 5 older executives and no younger executives at Travere Therapeutics. The oldest executive at Travere Therapeutics is Dr. William E. Rote Ph.D., Senior VP and Head of Research & Development, who is 61 years old. Learn More on Elizabeth E. Reed's age.

What is Elizabeth E. Reed's salary?

As the SVP of Travere Therapeutics, Inc., Ms. Reed earns $713,630.00 per year. There are 3 executives that earn more than Ms. Reed. The highest earning executive at Travere Therapeutics is Dr. Eric M. Dube Ph.D., President, CEO & Director, who commands a salary of $1,400,000.00 per year. Learn More on Elizabeth E. Reed's salary.

How do I contact Elizabeth E. Reed?

The corporate mailing address for Ms. Reed and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on Elizabeth E. Reed's contact information.

Has Elizabeth E. Reed been buying or selling shares of Travere Therapeutics?

Elizabeth E. Reed has not been actively trading shares of Travere Therapeutics during the last ninety days. Most recently, Elizabeth E. Reed sold 2,062 shares of the business's stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $8.96, for a transaction totalling $18,475.52. Following the completion of the sale, the senior vice president now directly owns 56,034 shares of the company's stock, valued at $502,064.64. Learn More on Elizabeth E. Reed's trading history.

Who are Travere Therapeutics' active insiders?

Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.

Are insiders buying or selling shares of Travere Therapeutics?

During the last year, insiders at the sold shares 19 times. They sold a total of 61,633 shares worth more than $592,310.91. The most recent insider tranaction occured on April, 11th when CFO Christopher R Cline sold 54 shares worth more than $363.96. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.

Information on this page was last updated on 4/11/2024.

Elizabeth E. Reed Insider Trading History at Travere Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2024Sell2,062$8.96$18,475.5256,034View SEC Filing Icon  
5/10/2023Sell825$16.59$13,686.7556,611View SEC Filing Icon  
2/1/2023Sell2,590$22.25$57,627.5057,436View SEC Filing Icon  
1/31/2022Sell1,350$27.40$36,990.00View SEC Filing Icon  
1/11/2022Sell5,000$27.40$137,000.00View SEC Filing Icon  
2/3/2021Sell3,175$28.91$91,789.25
See Full Table

Elizabeth E. Reed Buying and Selling Activity at Travere Therapeutics

This chart shows Elizabeth E Reed's buying and selling at Travere Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Travere Therapeutics Company Overview

Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $5.39
Low: $5.12
High: $5.50

50 Day Range

MA: $7.34
Low: $5.39
High: $8.71

2 Week Range

Now: $5.39
Low: $5.12
High: $22.75

Volume

1,484,532 shs

Average Volume

1,268,892 shs

Market Capitalization

$410.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.